ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$59.66 USD
-0.72 (-1.19%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $59.68 +0.02 (0.03%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ANIP 59.66 -0.72(-1.19%)
Will ANIP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Other News for ANIP
ANI Pharmaceuticals price target raised by $2 at Raymond James, here's why
ANI Pharmaceuticals Inc (ANIP) Trading 6.85% Higher on Sep 17
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals
ANI Pharmaceuticals’ Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target Price
ANI Pharmaceuticals Inc (ANIP) Shares Gap Down to $56.61 on Sep 16